IPO Year: 1992
Exchange: NASDAQ
SC TO-I/A - PDL BIOPHARMA, INC. (0000882104) (Subject)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
EFFECT - PDL BIOPHARMA, INC. (0000882104) (Filer)
POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
POS AM - PDL BIOPHARMA, INC. (0000882104) (Filer)
CAMBRIDGE, Mass. and NESS ZIONA, Israel, April 18, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE:PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced the appointment of Susan Blum to its Board of Directors. Ms. Blum was also appointed to serve as a member and chair of the audit committee of the Board. "We are pleased to welcome Susan Blum to our Board of Directors who joins BiomX at one of the most exciting periods in our company's history," said Jonathan Solomon, Chief Executive Officer of BiomX Inc. "For nearly two decades, Susan has held executive positions in both finance
SAN CARLOS, Calif., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology, today announced the appointment of Francis Sarena as Chief Operating Officer. Mr. Sarena will be responsible for leading strategic operations, driving business development, overseeing finance and investor relations and optimizing organizational functions. "We are thrilled to welcome Francis, an accomplished industry veteran, during this important phase of Apexigen's evolution," said Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer of Apexigen. "His deep biopharmaceut
SEATTLE--(BUSINESS WIRE)--Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, today announced that Natasha A. Hernday has joined Alpine’s Board of Directors. Ms. Hernday brings more than 20 years of experience in corporate development and corporate strategy. “I’m delighted to welcome Natasha to Alpine Immune Sciences’ Board at this important moment in our company’s history, as we build on our strategic partnership with AbbVie and leverage Alpine’s financial strength to further advance our development pipeline,” said Mitchell H. Gold, M.D., Executive